Vo Dang-Khoa, Trinh Kieu The Loan
College of Pharmacy, Gachon University, 191 Hambakmoe-ro, Yeonsu-gu, Incheon 21936, Republic of Korea.
BioNano Applications Research Center, Gachon University, 1342 Seongnam-daero, Sujeong-gu, Seongnam-si 13120, Gyeonggi-do, Republic of Korea.
Int J Mol Sci. 2024 Dec 8;25(23):13190. doi: 10.3390/ijms252313190.
Metabolomics has come to the fore as an efficient tool in the search for biomarkers that are critical for precision health approaches and improved diagnostics. This review will outline recent advances in biomarker discovery based on metabolomics, focusing on metabolomics biomarkers reported in cancer, neurodegenerative disorders, cardiovascular diseases, and metabolic health. In cancer, metabolomics provides evidence for unique oncometabolites that are important for early disease detection and monitoring of treatment responses. Metabolite profiling for conditions such as neurodegenerative and mental health disorders can offer early diagnosis and mechanisms into the disease especially in Alzheimer's and Parkinson's diseases. In addition to these, lipid biomarkers and other metabolites relating to cardiovascular and metabolic disorders are promising for patient stratification and personalized treatment. The gut microbiome and environmental exposure also feature among the influential factors in biomarker discovery because they sculpt individual metabolic profiles, impacting overall health. Further, we discuss technological advances in metabolomics, current clinical applications, and the challenges faced by metabolomics biomarker validation toward precision medicine. Finally, this review discusses future opportunities regarding the integration of metabolomics into routine healthcare to enable preventive and personalized approaches.
代谢组学已成为寻找生物标志物的有效工具,这些生物标志物对于精准医疗方法和改进诊断至关重要。本综述将概述基于代谢组学的生物标志物发现的最新进展,重点关注癌症、神经退行性疾病、心血管疾病和代谢健康方面报道的代谢组学生物标志物。在癌症中,代谢组学为独特的肿瘤代谢物提供了证据,这些代谢物对疾病早期检测和治疗反应监测很重要。对神经退行性疾病和精神健康障碍等病症的代谢物谱分析可以提供早期诊断,并揭示疾病机制,尤其是在阿尔茨海默病和帕金森病中。除此之外,与心血管和代谢紊乱相关的脂质生物标志物和其他代谢物在患者分层和个性化治疗方面很有前景。肠道微生物群和环境暴露也是生物标志物发现中的影响因素,因为它们塑造个体代谢谱,影响整体健康。此外,我们还讨论了代谢组学的技术进展、当前的临床应用以及代谢组学生物标志物验证在精准医学中面临的挑战。最后,本综述讨论了将代谢组学整合到常规医疗保健中以实现预防和个性化方法的未来机遇。